Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2024
2023
2022
2021
2020
2019

2022.08.30

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

2022.06.29

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

2022.05.26

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

2022.05.12

Adagene to Participate in Investor Conferences in May and June

2022.04.08

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Displaying 6 - 10 of 19

Shareholder Tools

© 2024 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn